Published in Annu Rev Med on January 01, 2008
Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med (2009) 3.58
A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano (2010) 2.27
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest (2011) 1.91
More effective nanomedicines through particle design. Small (2011) 1.80
Noble metal nanoparticles applications in cancer. J Drug Deliv (2011) 1.66
The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc (2010) 1.63
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine (Lond) (2011) 1.49
A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem Int Ed Engl (2009) 1.35
Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A (2010) 1.35
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A (2012) 1.32
Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano (2010) 1.31
Nanotechnology applications in surgical oncology. Annu Rev Med (2010) 1.31
Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem (2011) 1.30
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia (2009) 1.28
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Gold nanoparticles: From nanomedicine to nanosensing. Nanotechnol Sci Appl (2008) 1.21
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res (2010) 1.20
Chemistries for patterning robust DNA microbarcodes enable multiplex assays of cytoplasm proteins from single cancer cells. Chemphyschem (2010) 1.11
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates. Bioconjug Chem (2010) 1.08
Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin Drug Deliv (2010) 1.06
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05
Simultaneous enhancement of photothermal stability and gene delivery efficacy of gold nanorods using polyelectrolytes. ACS Nano (2009) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Nanomaterials for cancer therapy and imaging. Mol Cells (2011) 1.05
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther (2008) 0.99
Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano (2012) 0.99
Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem (2014) 0.97
Engineering the Properties of Metal Nanostructures via Galvanic Replacement Reactions. Mater Sci Eng R Rep (2010) 0.95
Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine (Lond) (2011) 0.93
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine (2010) 0.92
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Metal-organic frameworks as sensory materials and imaging agents. Inorg Chem (2013) 0.90
Stabilization of peptide vesicles by introducing inter-peptide disulfide bonds. Pharm Res (2009) 0.90
Biology takes centre stage. Nat Mater (2009) 0.89
Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles. Proc Natl Acad Sci U S A (2011) 0.89
Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol (2013) 0.85
Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release (2015) 0.85
Nucleic acid-based nanoengineering: novel structures for biomedical applications. Interface Focus (2011) 0.84
Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. Int J Nanomedicine (2015) 0.84
Ion-permeable membrane for on-chip preconcentration and separation of cancer marker proteins. Electrophoresis (2011) 0.84
Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem (2011) 0.84
Drug-initiated ring-opening polymerization of O-carboxyanhydrides for the preparation of anticancer drug-poly(O-carboxyanhydride) nanoconjugates. Biomacromolecules (2013) 0.83
Nanomaterials and autophagy: new insights in cancer treatment. Cancers (Basel) (2013) 0.83
Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol (2011) 0.83
Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine (2012) 0.82
Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications. Nano Today (2010) 0.81
Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials (2015) 0.81
Microfluidics and cancer: are we there yet? Biomed Microdevices (2013) 0.80
Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy. Int J Nanomedicine (2012) 0.80
Transgene delivery using poly(amino ether)-gold nanorod assemblies. Biotechnol Bioeng (2012) 0.80
The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system. Int J Mol Sci (2009) 0.80
Poly(iohexol) nanoparticles as contrast agents for in vivo X-ray computed tomography imaging. J Am Chem Soc (2013) 0.80
Synthesis and In vitro activity of ROMP-based polymer nanoparticles. J Mater Chem (2009) 0.79
Expanding imaging capabilities for microfluidics: applicability of darkfield internal reflection illumination (DIRI) to observations in microfluidics. PLoS One (2015) 0.79
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small (2015) 0.79
Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). Curr Opin Solid State Mater Sci (2012) 0.78
Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci U S A (2015) 0.78
PEG-b-AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting. J Mater Chem B Mater Biol Med (2015) 0.78
Targeted Nanotherapies for the Treatment of Surgical Diseases. Ann Surg (2016) 0.78
Nanotechnology applications in thoracic surgery. Eur J Cardiothorac Surg (2016) 0.77
Nanomechanical in situ monitoring of proteolysis of peptide by Cathepsin B. PLoS One (2009) 0.76
Developments in the use of nanocapsules in oncology. Braz J Med Biol Res (2013) 0.76
Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization". AAPS J (2014) 0.76
Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin. Beilstein J Org Chem (2015) 0.75
The Golden Age in Cancer Nanobiotechnology: Quo Vadis? Front Bioeng Biotechnol (2015) 0.75
Formation of nanoparticles by cooperative inclusion between (S)-camptothecin-modified dextrans and β-cyclodextrin polymers. Beilstein J Org Chem (2015) 0.75
Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment. Iran J Ped Hematol Oncol (2015) 0.75
Current applications and future prospects of nanomaterials in tumor therapy. Int J Nanomedicine (2017) 0.75
Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging. Nanoscale (2015) 0.75
Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) (2014) 0.75
Cardiovascular nanomedicine: a posse ad esse. Methodist Debakey Cardiovasc J (2012) 0.75
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. J Immunother Cancer (2015) 0.75
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice. PLoS One (2014) 0.75
Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy. Int J Mol Sci (2017) 0.75
Examining the Roles of Emulsion Droplet Size and Surfactant in the Interfacial Instability-Based Fabrication Process of Micellar Nanocrystals. Nanoscale Res Lett (2017) 0.75
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol (1972) 40.51
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc Soc Exp Biol Med (1955) 15.18
Monolithic microfabricated valves and pumps by multilayer soft lithography. Science (2000) 14.37
Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science (2001) 10.93
Printing proteins as microarrays for high-throughput function determination. Science (2000) 10.77
Nanostructures in biodiagnostics. Chem Rev (2005) 9.96
Nanotube molecular wires as chemical sensors Science (2000) 8.39
Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science (2003) 8.17
Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol (2005) 8.00
Targeted cancer therapy. Nature (2004) 7.81
Microfluidic large-scale integration. Science (2002) 7.64
Systems biology and new technologies enable predictive and preventative medicine. Science (2004) 7.59
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer (2006) 5.75
Continuous particle separation through deterministic lateral displacement. Science (2004) 5.60
Ultra-sensitive NEMS-based cantilevers for sensing, scanned probe and very high-frequency applications. Nat Nanotechnol (2007) 5.55
A microfabricated fluorescence-activated cell sorter. Nat Biotechnol (1999) 5.00
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Blood-on-a-chip. Annu Rev Biomed Eng (2005) 4.46
Array-based electrical detection of DNA with nanoparticle probes. Science (2002) 4.33
Quantum dots as cellular probes. Annu Rev Biomed Eng (2005) 4.19
11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med (2001) 3.94
Electrical detection of single viruses. Proc Natl Acad Sci U S A (2004) 3.83
Highly ordered nanowire arrays on plastic substrates for ultrasensitive flexible chemical sensors. Nat Mater (2007) 3.82
Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer (2002) 3.75
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol (2007) 3.36
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
A data integration methodology for systems biology. Proc Natl Acad Sci U S A (2005) 2.93
Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem (2006) 2.91
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. Proc Natl Acad Sci U S A (2000) 2.75
DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. J Am Chem Soc (2007) 2.42
Detection limits for nanoscale biosensors. Nano Lett (2005) 2.42
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35
Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods (1997) 2.34
Quantitative real-time measurements of DNA hybridization with alkylated nonoxidized silicon nanowires in electrolyte solution. J Am Chem Soc (2006) 2.22
Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem Biol (2007) 2.16
A microfluidic device for continuous, real time blood plasma separation. Lab Chip (2006) 2.07
Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods (2007) 1.99
Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. J Am Chem Soc (2005) 1.97
Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol (2006) 1.94
Functionalized micellar systems for cancer targeted drug delivery. Pharm Res (2007) 1.90
A label-free immunosensor array using single-chain antibody fragments. Proc Natl Acad Sci U S A (2005) 1.85
Microsample preparation by dielectrophoresis: isolation of malaria. Lab Chip (2002) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem (2007) 1.71
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med (2005) 1.63
Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol (2003) 1.62
Microchip device for cell lysis, multiplex PCR amplification, and electrophoretic sizing. Anal Chem (1998) 1.51
Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res (2005) 1.49
Modeling and optimization of high-sensitivity, low-volume microfluidic-based surface immunoassays. Biomed Microdevices (2005) 1.47
Continuous separation of lipid particles from erythrocytes by means of laminar flow and acoustic standing wave forces. Lab Chip (2004) 1.43
Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res (2005) 1.39
Isolation of plasma from whole blood using planar microfilters for lab-on-a-chip applications. Lab Chip (2005) 1.30
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res (2005) 1.29
Nanoliter scale microbioreactor array for quantitative cell biology. Biotechnol Bioeng (2006) 1.24
Quantitative proteomic analysis of myc-induced apoptosis: a direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4. J Biol Chem (2005) 1.18
Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem (2006) 1.14
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood (2004) 1.09
Molecularly targeted therapy: have the floodgates opened? Oncologist (2004) 1.08
A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat Med (2006) 1.03
Molecular monitoring of chronic myeloid leukemia. Semin Hematol (2003) 1.03
Cellular immunotherapy: antigen recognition is just the beginning. Springer Semin Immunopathol (2005) 0.92
Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. ScientificWorldJournal (2006) 0.89
Lipopolysaccharide microarrays for the detection of antibodies. J Immunol Methods (2005) 0.87
An improved panning technique for the selection of CD34+ human bone marrow hematopoietic cells with high recovery of early progenitors. Exp Hematol (1995) 0.86
Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. Anal Chem (2006) 0.86
Photopatterning of antibodies on biosensors. Bioconjug Chem (2000) 0.83
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res (2006) 3.22
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A (2009) 2.72
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol (2004) 2.32
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem (2007) 1.71
Lack of interferon response in animals to naked siRNAs. Nat Biotechnol (2004) 1.71
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng (2008) 1.60
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res (2006) 1.59
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A (2012) 1.52
Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem (2003) 1.44
A combustion-free methodology for synthesizing zeolites and zeolite-like materials. Nature (2003) 1.43
Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol (2005) 1.41
Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A (2011) 1.41
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther (2004) 1.40
Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem (2004) 1.40
Tin-containing zeolites are highly active catalysts for the isomerization of glucose in water. Proc Natl Acad Sci U S A (2010) 1.38
A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem (2005) 1.37
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng (2007) 1.36
Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem (2003) 1.35
Clinical developments in nanotechnology for cancer therapy. Pharm Res (2010) 1.23
Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A (2013) 1.19
Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm (2005) 1.19
Development of a nonviral gene delivery vehicle for systemic application. Bioconjug Chem (2002) 1.18
Mechanism of glucose isomerization using a solid Lewis acid catalyst in water. Angew Chem Int Ed Engl (2010) 1.17
Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug Chem (2003) 1.17
Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery. J Med Chem (2006) 1.16
Quantitating intracellular transport of polyplexes by spatio-temporal image correlation spectroscopy. Proc Natl Acad Sci U S A (2005) 1.12
Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J Control Release (2006) 1.11
Metalloenzyme-like catalyzed isomerizations of sugars by Lewis acid zeolites. Proc Natl Acad Sci U S A (2012) 1.08
A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem (2005) 1.08
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug Chem (2003) 1.01
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release (2012) 0.99
Cooperative catalysis by silica-supported organic functional groups. Chem Soc Rev (2008) 0.96
Multifunctional heterogeneous catalysts: SBA-15-containing primary amines and sulfonic acids. Angew Chem Int Ed Engl (2006) 0.91
Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug Chem (2003) 0.90
Synthetic biocompatible cyclodextrin-based constructs for local gene delivery to improve cutaneous wound healing. Bioconjug Chem (2004) 0.90
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol (2010) 0.90
Single cell kinetics of intracellular, nonviral, nucleic acid delivery vehicle acidification and trafficking. Bioconjug Chem (2005) 0.89
Single-antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm (2013) 0.89
Synthesis of a specified, silica molecular sieve by using computationally predicted organic structure-directing agents. Angew Chem Int Ed Engl (2014) 0.85
Nanomedicine targets cancer. Sci Am (2009) 0.84
Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers. Bioconjug Chem (2013) 0.84
Issues in the synthesis of crystalline molecular sieves: towards the crystallization of low framework-density structures. Chemphyschem (2004) 0.83
Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney Dis (2013) 0.82
Mechanical and dielectric properties of pure-silica-zeolite low-k materials. Angew Chem Int Ed Engl (2006) 0.80
A biodegradable filament for controlled drug delivery. J Control Release (2009) 0.80
Regeneration of rat sciatic nerve across a LactoSorb bioresorbable conduit with interposed short-segment nerve grafts. J Neurosurg (2003) 0.79
siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther (2015) 0.78
Design of heterogeneous catalysts via multiple active site positioning in organic-inorganic hybrid materials. J Am Chem Soc (2003) 0.78
Organized surface functional groups: cooperative catalysis via thiol/sulfonic acid pairing. J Am Chem Soc (2007) 0.78
Nanoscale organization of thiol and arylsulfonic acid on silica leads to a highly active and selective bifunctional, heterogeneous catalyst. J Am Chem Soc (2008) 0.77
Molecular conjugates. Adv Biochem Eng Biotechnol (2005) 0.77
Low-temperature, manganese oxide-based, thermochemical water splitting cycle. Proc Natl Acad Sci U S A (2012) 0.75
Zeolite synthesis using degradable structure-directing agents and pore-filling agents. J Phys Chem B (2005) 0.75
A solvent-free method for isotopically or radioactively labeling cyclodextrins and cyclodextrin-containing polymers. Bioconjug Chem (2006) 0.75
Mechanism of CIT-6 and VPI-8 crystallization from zincosilicate gels. Chemistry (2002) 0.75
Structure-directing agent location and non-centrosymmetric structure of fluoride-containing zeolite SSZ-55. J Phys Chem B (2006) 0.75
Organocations in zeolite synthesis: fused bicyclo [l.m.0] cations and the discovery of zeolite SSZ-48. J Am Chem Soc (2002) 0.75
Shape-selective oxidation of primary alcohols using perruthenate-containing zeolites. Chem Commun (Camb) (2003) 0.75
CAD/CAM restorations and secondary caries: a literature review with illustrations. Dent Update (2008) 0.75